Klemen Naveršnik
Klemen Naveršnik has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Marko Trampuž
Sandoz Development Center Slovenia, Lek Pharmaceuticals d.d., Verovškova ulica 57, 1526 Ljubljana, Slovenia
2 shared publications - Zdenko Časar
Faculty of Pharmacy, University of Ljubljana, Askerceva cesta 7, SI-1000 Ljubljana, Slovenia
2 shared publications Aleš Mrhar
Chair for Biopharmaceutics and Pharmacokinetics Faculty of Pharmacy University of Ljubljana Ljubljana Slovenia
1 shared publication- Markus Kiefer
Global Manufacturing Science & Technology, Novartis Technical Operations, Fabrikstrasse 2, Novartis AG, 4056 Basel, Switzerland
1 shared publication - Mateja Žnidarič
Sandoz Development Center Slovenia, Lek Pharmaceuticals d.d., Kolodvorska cesta 27, 1234 Mengeš, Slovenia
1 shared publication Maša Sinreih Tisnikar
Sandoz Development Center Slovenia, Lek Pharmaceuticals d.d., Verovškova ulica 57, 1526 Ljubljana, Slovenia
1 shared publication
Latest Publications
- Open Access
- 6 December 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
Why and How to Control P-Chirality in Phosphorothioated Therapeutic Oligonucleotides: Analytical Challenges Associated with Determination of Stereochemical Composition
A surge in the approval of therapeutic oligonucleotides since 2016 has made this class of chemical modalities anessential toolbox for addressing unmet medical needs in the realm of rare or difficult-to-treat diseases. Therapeutic oligonucleotidesare complex drugs, primarily due to the active pharmaceutical ingredient, which presents numerous oligonucleotide-specificimpurities that are challenging to address during the manufacturing process. A less common challenge is the control of thestereochemical composition of P-chiral morpholino and phosphorothioate therapeutic oligonucleotides. These are produced in anon-stereoselective manner, resulting in a mixture of different stereoisomers that collectively form the final drug substance. Thus, thecontrol of stereochemical composition has an important role in the manufacturing process of therapeutic oligonucleotides, either asan in-process control or a final characterization test. In this Perspective, we first present the current status of oligonucleotidetherapeutics, with a focus on phosphorothioate derivatives. We then highlight the regulatory framework for controlling thestereochemical composition of these drugs, provide brief insights into the biological significance of stereochemical composition forphosphorothioates, and discuss the origin of stereochemical composition in the synthetic and downstream processes. Subsequently,we provide an in-depth analysis of analytical methods used to determine the stereochemical composition of therapeuticoligonucleotides, including liquid chromatography approaches in various separation modes and emerging modern techniques like ionmobility spectrometry. Furthermore, capillary electrophoresis, duplex melting temperature, and NMR spectroscopy are alsodiscussed in the context of stereochemical composition analysis of therapeutic oligonucleotides. Finally, we highlight novelenzymatic methods for cleaving therapeutic oligonucleotides into smaller fragments that can be analyzed for stereochemicalcomposition using standard techniques.
- 6 December 2024
- Published by American Chemical Society (ACS) in Organic Process Research & Development
Open AccessWhy and How to Control P-Chirality in Phosphorothioated Therapeutic Oligonucleotides: Analytical Challenges Associated with Determination of Stereochemical Composition
A surge in the approval of therapeutic oligonucleotides since 2016 has made this class of chemical modalities anessential toolbox for addressing unmet medical needs in the realm of rare or difficult-to-treat diseases. Therapeutic oligonucleotidesare complex drugs, primarily due to the active pharmaceutical ingredient, which presents numerous oligonucleotide-specificimpurities that are challenging to address during the manufacturing process. A less common challenge is the control of thestereochemical composition of P-chiral morpholino and phosphorothioate therapeutic oligonucleotides. These are produced in anon-stereoselective manner, resulting in a mixture of different stereoisomers that collectively form the final drug substance. Thus, thecontrol of stereochemical composition has an important role in the manufacturing process of therapeutic oligonucleotides, either asan in-process control or a final characterization test. In this Perspective, we first present the current status of oligonucleotidetherapeutics, with a focus on phosphorothioate derivatives. We then highlight the regulatory framework for controlling thestereochemical composition of these drugs, provide brief insights into the biological significance of stereochemical composition forphosphorothioates, and discuss the origin of stereochemical composition in the synthetic and downstream processes. Subsequently,we provide an in-depth analysis of analytical methods used to determine the stereochemical composition of therapeuticoligonucleotides, including liquid chromatography approaches in various separation modes and emerging modern techniques like ionmobility spectrometry. Furthermore, capillary electrophoresis, duplex melting temperature, and NMR spectroscopy are alsodiscussed in the context of stereochemical composition analysis of therapeutic oligonucleotides. Finally, we highlight novelenzymatic methods for cleaving therapeutic oligonucleotides into smaller fragments that can be analyzed for stereochemicalcomposition using standard techniques.
- Open Access
Assessment of a Diverse Array of Nitrite Scavengers in Solution and Solid State: A Study of Inhibitory Effect on the Formation of Alkyl-Aryl and Dialkyl N-Nitrosamine Derivatives
The ubiquitous presence of mutagenic and potentially carcinogenic N-nitrosamine impurities in medicines has become a major issue in the pharmaceutical industry in recent years. Rigorous mitigation strategies to limit their amount in drug products are, therefore, needed. The removal of nitrite, which is a prerequisite reagent for the N-nitrosation of amines, has been acknowledged as one of the most promising strategies. We have conducted an extensive literature search to identify nineteen structurally diverse nitrite scavengers and screened their activity experimentally under pharmaceutically relevant conditions. In the screening phase, we have identified six compounds that proved to have the best nitrite scavenging properties: ascorbic acid (vitamin C), sodium ascorbate, maltol, propyl gallate, para-aminobenzoic acid (PABA), and l-cysteine. These were selected for investigation as inhibitors of the formation of N-methyl-N-nitrosoaniline (NMA) from N-methylaniline and N-nitroso-N’-phenylpiperazine (NPP) from N-phenylpiperazine in both solution and model tablets. Much faster kinetics of NMA formation compared to NPP was observed, but the former was less stable at high temperatures. Vitamin C, PABA, and l-cysteine were recognized as the most effective inhibitors under most studied conditions. The nitrite scavenging activity does not directly translate into N-nitrosation inhibitory effectiveness, indicating other reaction pathways may take place. The study presents an important contribution to identifying physiologically acceptable chemicals that could be added to drugs to prevent N-nitrosation during manufacture and storage.
Open AccessAssessment of a Diverse Array of Nitrite Scavengers in Solution and Solid State: A Study of Inhibitory Effect on the Formation of Alkyl-Aryl and Dialkyl N-Nitrosamine Derivatives
The ubiquitous presence of mutagenic and potentially carcinogenic N-nitrosamine impurities in medicines has become a major issue in the pharmaceutical industry in recent years. Rigorous mitigation strategies to limit their amount in drug products are, therefore, needed. The removal of nitrite, which is a prerequisite reagent for the N-nitrosation of amines, has been acknowledged as one of the most promising strategies. We have conducted an extensive literature search to identify nineteen structurally diverse nitrite scavengers and screened their activity experimentally under pharmaceutically relevant conditions. In the screening phase, we have identified six compounds that proved to have the best nitrite scavenging properties: ascorbic acid (vitamin C), sodium ascorbate, maltol, propyl gallate, para-aminobenzoic acid (PABA), and l-cysteine. These were selected for investigation as inhibitors of the formation of N-methyl-N-nitrosoaniline (NMA) from N-methylaniline and N-nitroso-N’-phenylpiperazine (NPP) from N-phenylpiperazine in both solution and model tablets. Much faster kinetics of NMA formation compared to NPP was observed, but the former was less stable at high temperatures. Vitamin C, PABA, and l-cysteine were recognized as the most effective inhibitors under most studied conditions. The nitrite scavenging activity does not directly translate into N-nitrosation inhibitory effectiveness, indicating other reaction pathways may take place. The study presents an important contribution to identifying physiologically acceptable chemicals that could be added to drugs to prevent N-nitrosation during manufacture and storage.
- 25 July 2022
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 111 (11) , 3108-3113
A Simple Non-Linear Kinetic Model to Evaluate Stability of a Pressure Sensitive Drug
- 25 July 2022
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 111 (11) , 3108-3113
A Simple Non-Linear Kinetic Model to Evaluate Stability of a Pressure Sensitive Drug
- 1 March 2016
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 500 (1-2) , 360-365
Humidity-corrected Arrhenius equation: The reference condition approach
- 1 March 2016
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 500 (1-2) , 360-365
Humidity-corrected Arrhenius equation: The reference condition approach
- Open Access
- 27 February 2014
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 16 (2) , e67
Routine Real-Time Cost-Effectiveness Monitoring of a Web-Based Depression Intervention: A Risk-Sharing Proposal
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet
- 27 February 2014
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 16 (2) , e67
Open AccessRoutine Real-Time Cost-Effectiveness Monitoring of a Web-Based Depression Intervention: A Risk-Sharing Proposal
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet